https://orcid.org/0000-0001-7721-7978
Key Points
Integration of ζ-deficient CARs into the CD3ζ gene allows generation of functional TCR-ablated CAR-T cells for allogeneic off-the-shelf use.
CD3ζ-editing platform allows CAR redirection of NK cells without affecting their canonical functions.
Abstract
Chimeric antigen receptor (CAR)-redirected immune cells hold significant therapeutic potential for oncology, autoimmune diseases, transplant medicine, and infections. All approved CAR-T therapies rely on personalized manufacturing using undirected viral gene transfer, which results in nonphysiological regulation of CAR-signaling and limits their accessibility due to logistical challenges, high costs and biosafety requirements. Random gene transfer modalities pose a risk of malignant transformation by insertional mutagenesis. Here, we propose a novel approach utilizing CRISPR-Cas gene editing to redirect T cells and natural killer (NK) cells with CARs. By transferring shorter, truncated CAR-transgenes lacking a main activation domain into the human CD3ζ (CD247) gene, functional CAR fusion-genes are generated that exploit the endogenous CD3ζ gene as the CAR’s activation domain. Repurposing this T/NK-cell lineage gene facilitated physiological regulation of CAR expression and redirection of various immune cell types, including conventional T cells, TCRγ/δ T cells, regulatory T cells, and NK cells. In T cells, CD3ζ in-frame fusion eliminated TCR surface expression, reducing the risk of graft-versus-host disease in allogeneic off-the-shelf settings. CD3ζ-CD19-CAR-T cells exhibited comparable leukemia control to TCRα chain constant (TRAC)-replaced and lentivirus-transduced CAR-T cells in vivo. Tuning of CD3ζ-CAR-expression levels significantly improved the in vivo efficacy. Notably, CD3ζ gene editing enabled redirection of NK cells without impairing their canonical functions. Thus, CD3ζ gene editing is a promising platform for the development of allogeneic off-the-shelf cell therapies using redirected killer lymphocytes.
References
1.
Kalos
M
, Levine
BL
, Porter
DL
, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia
. Sci Transl Med
. 2011
;3
(95
):95ra73
.2.
Liu
E
, Marin
D
, Banerjee
P
, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors
. N Engl J Med
. 2020
;382
(6
):545
-553
.3.
MacDonald
KG
, Hoeppli
RE
, Huang
Q
, et al. Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor
. J Clin Invest
. 2016
;126
(4
):1413
-1424
.4.
Roemhild
A
, Otto
NM
, Moll
G
, et al. Regulatory T cells for minimising immune suppression in kidney transplantation: phase I/IIa clinical trial
. BMJ
. 2020
;371
:m3734
.5.
Maude
SL
, Frey
N
, Shaw
PA
, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia
. N Engl J Med
. 2014
;371
(16
):1507
-1517
.6.
Neelapu
SS
, Locke
FL
, Bartlett
NL
, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma
. N Engl J Med
. 2017
;377
(26
):2531
-2544
.7.
Schuster
SJ
, Svoboda
J
, Chong
EA
, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas
. N Engl J Med
. 2017
;377
(26
):2545
-2554
.8.
Raje
N
, Berdeja
J
, Lin
Y
, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma
. N Engl J Med
. 2019
;380
(18
):1726
-1737
.9.
Geisler
C
, Kuhlmann
J
, Rubin
B
. Assembly, intracellular processing, and expression at the cell surface of the human alpha beta T cell receptor/CD3 complex. Function of the CD3-zeta chain
. J Immunol
. 1989
;143
(12
):4069
-4077
.10.
Irving
BA
, Weiss
A
. The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways
. Cell
. 1991
;64
(5
):891
-901
.11.
Moingeon
P
, Lucich
JL
, McConkey
DJ
, et al. CD3 zeta dependence of the CD2 pathway of activation in T lymphocytes and natural killer cells
. Proc Natl Acad Sci U S A
. 1992
;89
(4
):1492
-1496
.12.
Omer
B
, Cardenas
MG
, Pfeiffer
T
, et al. A costimulatory CAR improves TCR-based cancer immunotherapy
. Cancer Immunol Res
. 2022
;10
(4
):512
-524
.13.
Majzner
RG
, Ramakrishna
S
, Yeom
KW
, et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas
. Nature
. 2022
;603
(7903
):934
-941
.14.
Mougiakakos
D
, Krönke
G
, Völkl
S
, et al. CD19-targeted CAR T cells in refractory systemic lupus erythematosus
. N Engl J Med
. 2021
;385
(6
):567
-569
.15.
Mackensen
A
, Müller
F
, Mougiakakos
D
, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
. Nat Med
. 2022
;28
(10
):2124
-2132
.16.
Müller
F
, Boeltz
S
, Knitza
J
, et al. CD19-targeted CAR T cells in refractory antisynthetase syndrome
. Lancet
. 2023
;401
(10379
):815
-818
.17.
Eyquem
J
, Mansilla-Soto
J
, Giavridis
T
, et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
. Nature
. 2017
;543
(7643
):113
-117
.18.
Odak
A
, Yuan
H
, Feucht
J
, et al. Novel extragenic genomic safe harbors for precise therapeutic T cell engineering
. Blood
. 2023
;141
(22
):2698
-2712
.19.
Scholler
J
, Brady
TL
, Binder-Scholl
G
, et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells
. Sci Transl Med
. 2012
;4
(132
):132ra53
.20.
Fraietta
JA
, Nobles
CL
, Sammons
MA
, et al. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells
. Nature
. 2018
;558
(7709
):307
-312
.21.
Shah
NN
, Qin
H
, Yates
B
, et al. Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy
. Blood Adv
. 2019
;3
(15
):2317
-2322
.22.
Micklethwaite
KP
, Gowrishankar
K
, Gloss
BS
, et al. Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells
. Blood
. 2021
;138
(16
):1391
-1405
.23.
Bishop
DC
, Clancy
LE
, Simms
R
, et al. Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated with piggyBac-modified CD19 CAR T cells
. Blood
. 2021
;138
(16
):1504
-1509
.24.
Harrison
SJ
, Nguyen
T
, Rahman
M
, et al. CAR+ T-cell lymphoma post ciltacabtagene autoleucel therapy for relapsed refractory multiple myeloma [abstract]
. Blood
. 2023
;142
(suppl 1
):6939
.25.
Wagner
DL
, Koehl
U
, Chmielewski
M
, Scheid
C
, Stripecke
R
. Review: sustainable clinical development of CAR-T cells-switching from viral transduction towards CRISPR-cas gene editing
. Front Immunol
. 2022
;13
:865424
.26.
Müller
TR
, Jarosch
S
, Hammel
M
, et al. Targeted T cell receptor gene editing provides predictable T cell product function for immunotherapy
. Cell Rep Med
. 2021
;2
(8
):100374
.27.
MacLeod
DT
, Antony
J
, Martin
AJ
, et al. Integration of a CD19 CAR into the TCR alpha chain locus streamlines production of allogeneic gene-edited CAR T cells
. Mol Ther
. 2017
;25
(4
):949
-961
.28.
Dai
X
, Park
JJ
, Du
Y
, et al. One-step generation of modular CAR-T cells with AAV-Cpf1
. Nat Methods
. 2019
;16
(3
):247
-254
.29.
Wiebking
V
, Lee
CM
, Mostrel
N
, et al. Genome editing of donor-derived T-cells to generate allogenic chimeric antigen receptor-modified T cells: optimizing αβ T cell-depleted haploidentical hematopoietic stem cell transplantation
. Haematologica
. 2021
;106
(3
):847
-858
.30.
Zhang
J
, Hu
Y
, Yang
J
, et al. Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL
. Nature
. 2022
;609
(7926
):369
-374
.31.
Allen
AG
, Khan
SQ
, Margulies
CM
, et al. A highly efficient transgene knock-in technology in clinically relevant cell types
. Nat Biotechnol
. 2024
;42
(3
):458
-469
.32.
Torikai
H
, Reik
A
, Liu
P-Q
, et al. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR
. Blood
. 2012
;119
(24
):5697
-5705
.33.
Kath
J
, Du
W
, Pruene
A
, et al. Pharmacological interventions enhance virus-free generation of TRAC-replaced CAR T cells
. Mol Ther Methods Clin Dev
. 2022
;25
:311
-330
.34.
Roth
TL
, Puig-Saus
C
, Yu
R
, et al. Reprogramming human T cell function and specificity with non-viral genome targeting
. Nature
. 2018
;559
(7714
):405
-409
.35.
Nguyen
DN
, Roth
TL
, Li
PJ
, et al. Polymer-stabilized Cas9 nanoparticles and modified repair templates increase genome editing efficiency
. Nat Biotechnol
. 2020
;38
(1
):44
-49
.36.
Turchiano
G
, Andrieux
G
, Klermund
J
, et al. Quantitative evaluation of chromosomal rearrangements in gene-edited human stem cells by CAST-Seq
. Cell Stem Cell
. 2021
;28
(6
):1136
-1147.e5
.37.
Rhiel
M
, Geiger
K
, Andrieux
G
, et al. T-CAST: an optimized CAST-Seq pipeline for TALEN confirms superior safety and efficacy of obligate-heterodimeric scaffolds
. Front Genome
. 2023
;5
:1130736
.38.
Braun
T
, Pruene
A
, Darguzyte
M
, et al. Non-viral TRAC-knocked-in CD19KICAR-T and gp350KICAR-T cells tested against Burkitt lymphomas with type 1 or 2 EBV infection: in vivo cellular dynamics and potency
. Front Immunol
. 2023
;14
:1086433
.39.
Hermans
IF
, Silk
JD
, Yang
J
, et al. The VITAL assay: a versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo
. J Immunol Methods
. 2004
;285
(1
):25
-40
.40.
Künkele
A
, Taraseviciute
A
, Finn
LS
, et al. Preclinical assessment of CD171-directed CAR T-cell adoptive therapy for childhood neuroblastoma: CE7 epitope target safety and product manufacturing feasibility
. Clin Cancer Res
. 2017
;23
(2
):466
-477
.41.
Textor
A
, Listopad
JJ
, Wührmann
LL
, et al. Efficacy of CAR T-cell therapy in large tumors relies upon stromal targeting by IFNγ
. Cancer Res
. 2014
;74
(23
):6796
-6805
.42.
Ahmed
N
, Brawley
VS
, Hegde
M
, et al. Human epidermal growth factor receptor 2 (HER2) -specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma
. J Clin Oncol
. 2015
;33
(15
):1688
-1696
.43.
Ahmed
N
, Brawley
V
, Hegde
M
, et al. HER2-specific chimeric antigen receptor–modified virus-specific T cells for progressive glioblastoma
. JAMA Oncol
. 2017
;3
(8
):1094
-1101
.44.
Hegde
M
, Joseph
SK
, Pashankar
F
, et al. Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma
. Nat Commun
. 2020
;11
(1
):3549
.45.
Yang
S
, Cohen
CJ
, Peng
PD
, et al. Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition
. Gene Ther
. 2008
;15
(21
):1411
-1423
.46.
Liu
Z
, Chen
O
, Wall
JBJ
, et al. Systematic comparison of 2A peptides for cloning multi-genes in a polycistronic vector
. Sci Rep
. 2017
;7
(1
):2193
.47.
Noyan
F
, Zimmermann
K
, Hardtke-Wolenski
M
, et al. Prevention of allograft rejection by use of regulatory T cells with an MHC-specific chimeric antigen receptor
. Am J Transplant
. 2017
;17
(4
):917
-930
.48.
Deniger
DC
, Switzer
K
, Mi
T
, et al. Bispecific T-cells expressing polyclonal repertoire of endogenous γδ T-cell receptors and introduced CD19-specific chimeric antigen receptor
. Mol Ther
. 2013
;21
(3
):638
-647
.49.
Daher
M
, Rezvani
K
. Outlook for new CAR-based therapies with a focus on CAR NK cells: what lies beyond CAR-engineered T cells in the race against cancer
. Cancer Discov
. 2021
;11
(1
):45
-58
.50.
Naeimi Kararoudi
M
, Tullius
BP
, Chakravarti
N
, et al. Genetic and epigenetic modification of human primary NK cells for enhanced antitumor activity
. Semin Hematol
. 2020
;57
(4
):201
-212
.51.
Robbins
GM
, Wang
M
, Pomeroy
EJ
, Moriarity
BS
. Nonviral genome engineering of natural killer cells
. Stem Cell Res Ther
. 2021
;12
(1
):350
.52.
Klingemann
H
. The NK-92 cell line-30 years later: its impact on natural killer cell research and treatment of cancer
. Cytotherapy
. 2023
;25
(5
):451
-457
.53.
Barden
M
, Holzinger
A
, Velas
L
, et al. CAR and TCR form individual signaling synapses and do not cross-activate, however, can co-operate in T cell activation
. Front Immunol
. 2023
;14
:1110482
.54.
Qasim
W
. Genome edited allogeneic donor “universal” chimeric antigen receptor T Cells
. Blood
. 2023;141(8):835-845
.55.
Kath
J
, Du
W
, Martini
S
, et al. CAR NK-92 cell-mediated depletion of residual TCR+ cells for ultrapure allogeneic TCR-deleted CAR T-cell products
. Blood Adv
. 2023
;7
(15
):4124
-4134
.56.
Weber
EW
, Parker
KR
, Sotillo
E
, et al. Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling
. Science
. 2021
;372
(6537
):eaba1786
.57.
Ruella
M
, Xu
J
, Barrett
DM
, et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell
. Nat Med
. 2018
;24
(10
):1499
-1503
.58.
Gomes-Silva
D
, Mukherjee
M
, Srinivasan
M
, et al. Tonic 4-1BB costimulation in chimeric antigen receptors impedes T Cell survival and is vector dependent
. Cell Rep
. 2017
;21
(1
):17
-26
.59.
Rodriguez-Marquez
P
, Calleja-Cervantes
ME
, Serrano
G
, et al. CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome
. Sci Adv
. 2022
;8
(39
):eabo0514
.60.
Ho
J-Y
, Wang
L
, Liu
Y
, et al. Promoter usage regulating the surface density of CAR molecules may modulate the kinetics of CAR-T cells in vivo
. Mol Ther Methods Clin Dev
. 2021
;21
:237
-246
.61.
Flugel
CL
, Majzner
RG
, Krenciute
G
, et al. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours
. Nat Rev Clin Oncol
. 2023
;20
(1
):49
-62
.62.
Attaf
M
, Legut
M
, Cole
DK
, Sewell
AK
. The T cell antigen receptor: the Swiss army knife of the immune system
. Clin Exp Immunol
. 2015
;181
(1
):1
-18
.63.
Roberts
JL
, Lauritsen
JPH
, Cooney
M
, et al. T−B+NK+ severe combined immunodeficiency caused by complete deficiency of the CD3ζ subunit of the T-cell antigen receptor complex
. Blood
. 2007
;109
(8
):3198
-3206
.64.
Valés-Gómez
M
, Esteso
G
, Aydogmus
C
, et al. Natural killer cell hyporesponsiveness and impaired development in a CD247-deficient patient
. J Allergy Clin Immunol
. 2016
;137
(3
):942
. 5.e4.65.
Dahlvang
JD
, Dick
JK
, Sangala
JA
, et al. Ablation of SYK kinase from expanded primary human NK cells via CRISPR/Cas9 enhances cytotoxicity and cytokine production
. J Immunol
. 2023
:ji2200488
.66.
Shy
BR
, Vykunta
VS
, Ha
A
, et al. High-yield genome engineering in primary cells using a hybrid ssDNA repair template and small-molecule cocktails
. Nat Biotechnol
. 2023
;41
(4
):521
-531
.67.
Qasim
W
, Zhan
H
, Samarasinghe
S
, et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells
. Sci Transl Med
. 2017
;9
(374
):eaaj2013
.68.
Benjamin
R
, Graham
C
, Yallop
D
, et al. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies
. Lancet
. 2020
;396
(10266
):1885
-1894
.69.
Wagner
DL
, Fritsche
E
, Pulsipher
MA
, et al. Immunogenicity of CAR T cells in cancer therapy
. Nat Rev Clin Oncol
. 2021
;18
(6
):379
-393
.70.
Prinzing
B
, Zebley
CC
, Petersen
CT
, et al. Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity
. Sci Transl Med
. 2021
;13
(620
):eabh0272
.71.
Carnevale
J
, Shifrut
E
, Kale
N
, et al. RASA2 ablation in T cells boosts antigen sensitivity and long-term function
. Nature
. 2022
;609
(7925
):174
-182
.72.
Wiebking
V
, Patterson
JO
, Martin
R
, et al. Metabolic engineering generates a transgene-free safety switch for cell therapy
. Nat Biotechnol
. 2020
;38
(12
):1441
-1450
.73.
Torikai
H
, Reik
A
, Soldner
F
, et al. Toward eliminating HLA class I expression to generate universal cells from allogeneic donors
. Blood
. 2013
;122
(8
):1341
-1349
.74.
Kagoya
Y
, Guo
T
, Yeung
B
, et al. Genetic ablation of HLA class I, class II, and the T-cell receptor enables allogeneic T cells to be used for adoptive T-cell therapy
. Cancer Immunol Res
. 2020
;8
(7
):926
-936
.75.
Pomeroy
EJ
, Hunzeker
JT
, Kluesner
MG
, et al. A genetically engineered primary human natural killer cell platform for cancer immunotherapy
. Mol Ther
. 2020
;28
(1
):52
-63
.76.
Daher
M
, Basar
R
, Gokdemir
E
, et al. Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells
. Blood
. 2021
;137
(5
):624
-636
.77.
Diorio
C
, Murray
R
, Naniong
M
, et al. Cytosine base editing enables quadruple-edited allogeneic CAR-T cells for T-ALL
. Blood
. 2022
;140
(6
):619
-629
.78.
Komor
AC
, Kim
YB
, Packer
MS
, Zuris
JA
, Liu
DR
. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage
. Nature
. 2016
;533
(7603
):420
-424
.79.
Gaudelli
NM
, Komor
AC
, Rees
HA
, et al. Programmable base editing of A·T to G·C in genomic DNA without DNA cleavage
. Nature
. 2017
;551
(7681
):464
-471
.80.
Glaser
V
, Flugel
C
, Kath
J
, et al. Combining different CRISPR nucleases for simultaneous knock-in and base editing prevents translocations in multiplex-edited CAR T cells
. Genome Biol
. 2023
;24
(1
):89
.© 2024 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
2024
You do not currently have access to this content.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal